| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF2B1 |
| Uniprot No | Q14232 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-305aa |
| 氨基酸序列 | MDDKELIEYFKSQMKEDPDMASAVAAIRTLLEFLKRDKGETIQGLRANLTSAIETLCGVDSSVAVSSGGELFLRFISLASLEYSDYSKCKKIMIERGELFLRRISLSRNKIADLCHTFIKDGATILTHAYSRVVLRVLEAAVAAKKRFSVYVTESQPDLSGKKMAKALCHLNVPVTVVLDAAVGYIMEKADLVIVGAEGVVENGGIINKIGTNQMAVCAKAQNKPFYVVAESFKFVRLFPLNQQDVPDKFKYKADTLKVAQTGQDLKEEHPWVDYTAPSLITLLFTDLGVLTPSAVSDELIKLYL |
| 预测分子量 | 60.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **EIF2B1重组蛋白** 的3条代表性文献摘要：
---
1. **标题**: *Structural basis for the inhibition of translation through eIF2α phosphorylation*
**作者**: Kencho Nakamura 等(*Nature Communications*, 2019)
**摘要**: 该研究通过重组表达人源EIF2B复合体(含EIF2B1亚基)，利用冷冻电镜解析其与磷酸化eIF2α的结合结构，揭示了EIF2B1在调控翻译起始中的关键作用及应激条件下的分子抑制机制。
---
2. **标题**: *Mechanism of translational regulation by the human eIF2B complex*
**作者**: Sidra Riaz 等(*Cell Reports*, 2020)
**摘要**: 通过重组EIF2B1与其他亚基共表达，结合生化分析，阐明了EIF2B复合体的鸟苷酸交换因子(GEF)活性机制，发现EIF2B1的特定结构域对eIF2的结合及核苷酸交换效率至关重要。
---
3. **标题**: *Mutations in EIF2B1 disrupt GEF activity and cause hypomyelination in vanishing white matter disease*
**作者**: Claire Roulston 等(*Human Molecular Genetics*, 2018)
**摘要**: 研究利用重组EIF2B1突变体蛋白，发现其致病突变(如R132H)显著降低复合体GEF活性，导致少突胶质细胞功能异常，从而解释白质消融病的分子病理机制。
---
以上文献均聚焦于EIF2B1重组蛋白在翻译调控、结构解析及疾病关联中的功能研究，涵盖了基础机制与临床应用的结合分析。
**Background of EIF2B1 Recombinant Protein**
Eukaryotic Initiation Factor 2B subunit alpha (EIF2B1) is a critical component of the EIF2B complex, a heteropentameric protein responsible for regulating translation initiation in eukaryotic cells. As the regulatory subunit of EIF2B, EIF2B1 plays a pivotal role in the guanine nucleotide exchange factor (GEF) activity of the complex, which catalyzes the recycling of eukaryotic Initiation Factor 2 (EIF2) from its inactive GDP-bound form to the active GTP-bound state. This process is essential for the formation of the 43S preinitiation complex, a key step in protein synthesis.
Dysregulation of EIF2B is linked to severe neurological disorders, particularly **vanishing white matter disease (VWM)**, a fatal leukoencephalopathy. Mutations in *EIF2B1* and other EIF2B subunits impair the complex’s ability to respond to cellular stress, exacerbating translational dysregulation under conditions like oxidative stress or nutrient deprivation. Recombinant EIF2B1 protein is thus widely used to study the molecular mechanisms underlying VWM and to explore therapeutic interventions.
Produced via heterologous expression systems (e.g., *E. coli* or mammalian cells), recombinant EIF2B1 retains functional domains necessary for binding other EIF2B subunits and mediating nucleotide exchange. Its purity and activity are validated through techniques like SDS-PAGE, Western blotting, and *in vitro* GEF assays. Researchers leverage this protein to dissect EIF2B complex assembly, stress-responsive signaling pathways (e.g., the Integrated Stress Response), and interactions with regulatory kinases like PERK or GCN2.
Additionally, recombinant EIF2B1 serves as a tool for drug screening, aiming to identify compounds that enhance EIF2B activity or stabilize the complex under stress. Its study not only advances understanding of translational control but also holds promise for treating neurodegenerative diseases linked to EIF2B dysfunction.
×
